Hypersomnia with ADHD: a possible subtype of narcolepsy type 2
- 21 Downloads
Patients with attention deficit/hyperactivity disorder (ADHD) suffer from hypersomnia; indeed, we have often encountered ADHD patients that fulfill the diagnostic criteria for narcolepsy type 2 (NA 2). Because not all patients with NA 2 carry the HLA-DQB1*06:02 allele, which is closely associated with narcolepsy type 1 (NA 1), NA 2 is believed to be heterogeneous. To reveal the contribution of ADHD in hypersomnia, we studied the characteristics of hypersomnia patients with ADHD, especially those diagnosed with NA 2. Participants were 77 of 185 consecutive outpatients who were diagnosed with NA 2 or idiopathic hypersomnia. We investigated sleep variables in (a) participants with hypersomnia with/without ADHD and (b) patients with NA 2 with/without ADHD and those with/without the DQB1*06:02 allele. The proportion of those diagnosed with NA 2 was higher in hypersomnia patients with ADHD compared to those without ADHD. None of the NA 2 patients with ADHD carried the narcolepsy-specific DQB1*06:02 allele. These patients with NA 2 with ADHD exhibited short REM latencies on the MSLT (similarly to DQB1*06:02-positive patients with NA 2 without ADHD), but less REM-related phenomena than patients with NA 2 without ADHD. Hypersomnia patients with ADHD tended to show short REM latencies, and fulfilled NA 2 diagnostic criteria in the absence of the DQB1*06:02 allele, suggesting a different etiology from NA 1. These findings support the hypotheses of noradrenergic dysregulation and delayed brain maturation that have been proposed for the pathophysiology of ADHD.
KeywordsAttention deficit/hyperactivity disorder (ADHD) Sleep onset REM periods (SOREMPs) Excessive daytime sleepiness Narcolepsy type 2 HLA-DQB1*06:02
The authors wish to thank Ms. Kaori Sasaki and Mr. Shinya Kimura for their help to analyze PSG and MSLT data.
Compliance with ethical standards
Conflict of interest
All authors have no conflict of interest regarding this paper.
Ethical committee permission
The Ethics Committee of Institute of Neuropsychiatry, Permission Number 119.
All study participants provided informed consent.
- 6.American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien: American Academy of Sleep Medicine; 2014.Google Scholar
- 7.Han F, Lin L, Schormair B, Pizza F, Plazzi G, Ollila HM, Nevsimalova S, Jennum P, Knudsen S, Winkelmann J, Coquillard C, Babrzadeh F, Strom TM, Wang C, Mindrinos M, Vina MF, Mignot E. HLA DQB1*06:02 Negative Narcolepsy with Hypocretin/Orexin Deficiency. Sleep. 2014;37(10):1601–8.CrossRefPubMedCentralPubMedGoogle Scholar
- 15.Littner MR, Kushida C, Wise M, Davila DG, Morgenthaler T, Lee-Chiong T, Hirshkowitz M, Daniel LL, Bailey D, Berry RB, Kapen S, Kramer M, Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep. 2005;28(1):113–21.CrossRefPubMedGoogle Scholar
- 21.Chou T-L, Chia S, Shang C-Y, Gau SS-F. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: a counting Stroop functional MRI study. Eur Neuropsychopharmacol. 2015;25(12):2300–10.CrossRefPubMedGoogle Scholar
- 22.Asherson P, Bushe C, Saylor K, Tanaka Y, Deberdt W, Upadhyaya H. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials. J Psychopharmacol. 2014;28(9):837–46.CrossRefPubMedCentralPubMedGoogle Scholar
- 30.Mignot E, Lin L, Rogers W, Honda Y, Qiu X, Lin X, Okun M, Hohjoh H, Miki T, Hsu S, Leffell M, Grumet F, Fernandez-Vina M, Honda M, Risch N. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet. 2001;68(3):686–99.CrossRefPubMedCentralPubMedGoogle Scholar